US FDA approves expanded use of Bristol's cancer cell therapy-February 2024-www.financetom.com

US FDA approves expanded use of Bristol's cancer cell therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves expanded use of Bristol's cancer cell therapy

May 15, 2024 2:20 PM

May 15 (Reuters) - The U.S. Food and Drug Administration

on Wednesday approved the expanded use of Bristol Myers Squibb's ( BMY )

cancer cell therapy Breyanzi to include the treatment of

adults with a type of blood cancer that has returned or has not

responded to prior treatments.

Previous page： --Exxon Mobil Plans New Guyana Project to Boost Oil Output, Bloomberg Says Next page： Why GlycoMimetics Stock is Trading Higher Monday

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Exxon Mobil Plans New Guyana Project to Boost Oil Output, Bloomberg Says

Jun 25, 2024

12:02 PM EDT, 06/25/2024 (MT Newswires) -- Price: 113.66, Change: -0.39, Percent Change: -0.34 ...

Why GlycoMimetics Stock is Trading Higher Monday

Jun 25, 2024

GlycoMimetics, Inc. ( GLYC ) stock is moving higher Monday after its chief medical officer disclosed the purchase of company stock. The Details: On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305,000 shares of the company. Rock purchased the shares at an average price of 26 cents. How To Buy GlycoMimetics Stock An...

DoubleVerify Q1 Results, 2024 Outlook Raise Questions on Growth Prospects, Morgan Stanley Says

Jun 25, 2024

12:10 PM EDT, 06/25/2024 (MT Newswires) -- DoubleVerify's ( DV ) disappointing Q1 results and its 2024 guidance raise questions about the company's growth prospects, Morgan Stanley said in a Tuesday note. Morgan Stanley said the firm now needs to address concerns around slower large customer growth, softer open web ad spend and weaker product fit in CTV/social. While we...

Meta Materials, Former CEOs Face Charges of Market Manipulation, Fraud, SEC Says

Jun 25, 2024

12:05 PM EDT, 06/25/2024 (MT Newswires) -- Meta Materials ( MMAT ) and its former chief executive officers, John Brda and George Palikaras, face charges of market manipulation and fraud from the US Securities and Exchange Commission, the agency said Tuesday. Meta Materials ( MMAT ) agreed to settle the charges in an administrative proceeding, while the litigation against Brda...